ストックスクリーナーアプリを入手
4.25
0.23%
-0.010
Coya Therapeutics Inc (COYA) 最新ニュース
ALS Researchers Use Stratification, Diverse Endpoints To Address Heterogeneity - Clinical Leader
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's - MSN
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Mark H Pavao Net Worth (2026) - GuruFocus
COYA Options Volatility — NASDAQ:COYA - TradingView
COYA Options Chain — NASDAQ:COYA - TradingView
Is Coya (COYA) Stock Safe to Buy Now | COYA Q4 Earnings: Misses Estimates by $0.06Social Investment Platform - Newser
COYA PE Ratio & Valuation, Is COYA Overvalued - Intellectia AI
COYA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Report: Is Coya Therapeutics Inc impacted by rising ratesTrade Analysis Report & High Accuracy Trade Alerts - baoquankhu1.vn
Coya Therapeutics Is Maintained at Buy by D. Boral Capital - Moomoo
Coya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Market Review: Is Coya Therapeutics Inc benefiting from innovation trends2026 Catalysts & Accurate Entry/Exit Alerts - baoquankhu1.vn
Coya Therapeutics (COYA) director receives 10,000 stock options at $4.53 - Stock Titan
New Coya Therapeutics (COYA) director Mark H. Pavao files initial Form 3 - Stock Titan
Stop Loss: Will Coya Therapeutics Inc outperform its industry peers2026 Bull vs Bear & Technical Pattern Based Signals - baoquankhu1.vn
Market Leaders: How do insiders feel about Coya Therapeutics Inc2026 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS - Business Wire
Coya Therapeutics Announces Leadership Changes and New Director - The Globe and Mail
Coya Therapeutics founder steps down, adds new director By Investing.com - Investing.com Australia
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent - PharmiWeb.com
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director - BioSpace
COYA: Treg-focused therapies show promise in neurodegeneration, with pivotal trials underway - TradingView — Track All Markets
Investor Presentation (04/02/2026 00: 00 - marketscreener.com
Founder steps down as Coya Therapeutics (COYA) adds independent director Mark Pavao - Stock Titan
Coya Therapeutics founder steps down, adds new director - Investing.com
Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street - The Globe and Mail
Portfolio Update: Is Coya Therapeutics Inc forming higher highs and higher lows2026 Market Mood & Reliable Intraday Trade Plans - baoquankhu1.vn
Death Cross: How do insiders feel about Coya Therapeutics IncExit Point & Daily Profit Focused Screening - baoquankhu1.vn
Brokerages Set Coya Therapeutics, Inc. (NASDAQ:COYA) PT at $16.00 - Defense World
Aug Sentiment: Is Coya Therapeutics Inc forming higher highs and higher lows2026 Retail Activity & Technical Buy Zone Confirmation - baoquankhu1.vn
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - MSN
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) - The Globe and Mail
BTIG Reiterates Coya Therapeutics (COYA) Buy Recommendation - MSN
HC Wainwright Analysts Decrease Earnings Estimates for COYA - marketbeat.com
What is HC Wainwright’s Estimate for COYA Q1 Earnings? - Defense World
Sell Signal: How much upside does Coya Therapeutics Inc have2026 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at HC Wainwright - Defense World
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President a - pharmiweb.com
What is HC Wainwright's Estimate for COYA Q1 Earnings? - MarketBeat
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO - BioSpace
Coya Therapeutics' (COYA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating - TipRanks
Coya Therapeutics (COYA) Analyst Rating Reiterated at 'Buy' by H - GuruFocus
[EFFECT] Coya Therapeutics, In... | COYA SEC FilingForm EFFECT - Stock Titan
ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
CEO Moves: Can Coya Therapeutics Inc sustain earnings growthInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn
2.52M-share resale registration by Coya Therapeutics (NASDAQ: COYA) after Jan 2026 placement - stocktitan.net
Coya Therapeutics (COYA): Analyst Jason Kolbert Maintains Buy Ra - GuruFocus
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):